retatrutide triple agonist gip glp-1 glucagon receptor Retatrutide: How the Compares to Tirzepatide The power of three: Retatrutide's

Survodutide also reduced waist circumference, an indicator of metabolic health.

When GLP-1 receptor agonists (GLP-1RAs) were first approved over a decade ago, their primary indication was simple: help people with Type 2 diabetes manage their blood sugar

The European Medicines Agency has issued a positive recommendation on the same indication

Specifically, the trial reported an average weight loss of 17.5% and 24.4% at 24 and 48 weeks, respectively

Thirteen trials involving 5,807 participants were identified

Their potential for disease modification and symptom relief, particularly in specific phenotypes, supports their further exploration as part of a personalized treatment approach.